Literature DB >> 7885166

Premalignant epithelium and microinvasive cancer of the vocal fold: the evolution of phonomicrosurgical management.

S M Zeitels1.   

Abstract

Phonomicrosurgical treatment of premalignant vocal fold epithelium and microinvasive cancer combines principles of surgical oncology with advanced laryngoscopic microsurgical-techniques. This treatment is guided by mucosal-wave theory of voice production and strives not only to cure the disease but also to achieve optimal vocal function. Surgical techniques developed during the past two centuries have improved methods for vocal fold visualization, tissue retrieval, and tissue evaluation. Examination of the evolution of these surgical techniques reveals the incomplete convergence of laryngoscopic surgical theory with both the concept of premalignancy and the anatomical-physiological principles of voice production. This historical review, which helps to explain the lack of consensus about current treatment options, led to a series of four investigations. They were conducted with the aim of developing a laryngoscopic (phonomicrosurgical) management approach for improving the treatment of premalignant and microinvasive vocal fold epithelium. In the first of four investigations, 42 patients (each of whom had a significant smoking history) underwent microlaryngoscopic biopsy of 52 vocal fold lesions. These lesions, which were suspicious for atypia or malignancy and were confined to the musculomembranous vocal fold, were mapped according to surface involvement and depth of penetration. Review of the maps revealed that 27 of the 52 lesions involved only the superior/ventricular surface. For these patients, the entire layered vocal fold structure could potentially be preserved on the medial/vocalizing surface. Twenty-five of the 52 lesions involved both the superior/ventricular surface and the medial/vocalizing surface. No lesion involved only the medial surface. These data suggest that (in smokers) geographic localization of keratotic and erythroplastic lesions on the superior/ventricular surface of the musculomembranous vocal fold are likely to contain atypia. This characteristic facilitates the appropriate selection of patients for biopsy and may spare individuals, who have lesions resulting from hyperfunctional dysphonia and/or gastroesophageal reflux, from unnecessary biopsy. These two disorders typically result in pathology on the medial and/or posterior glottal surfaces. In order to determine whether a directed biopsy or an excisional biopsy approach is preferable for obtaining an accurate diagnosis, all specimens underwent whole-mount sectioning for three-dimensional histopathological analysis. Keratosis was noted: without atypia in 14; with atypia in 27; and with carcinoma in 11. The severity of the atypia usually varied throughout each specimen. The surface appearance of the lesion was not a reliable prognosticator of the severity of dysplasia either between patients or in different areas of the same lesion; therefore, excisional biopsy and whole-mount, multiple-section histopathological analysis were necessary for obtaining an accurate diagnosis.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 7885166     DOI: 10.1288/00005537-199503001-00001

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  21 in total

1.  Commentary on why laryngeal stroboscopy really works: clarifying misconceptions surrounding Talbot's law and the persistence of vision.

Authors:  Daryush D Mehta; Dimitar D Deliyski; Robert E Hillman
Journal:  J Speech Lang Hear Res       Date:  2010-10       Impact factor: 2.297

2.  Oncological outcome after CO2 laser cordectomy for early-stage glottic carcinoma.

Authors:  C Bocciolini; L Presutti; P Laudadio
Journal:  Acta Otorhinolaryngol Ital       Date:  2005-04       Impact factor: 2.124

3.  The impact of laryngeal dysplasia on the development of laryngeal squamous cell carcinoma.

Authors:  J C Luers; K Sircar; U Drebber; D Beutner
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-08-30       Impact factor: 2.503

4.  One-year follow-up results of combined use of CO2 laser and cold instrumentation for Reinke's edema surgery in professional voice users.

Authors:  Gursel Dursun; Ozan Bagis Ozgursoy; Ozgur Kemal; Isil Coruh
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-04-13       Impact factor: 2.503

5.  [Optical coherence tomography in the diagnosis of vocal folds].

Authors:  K Lüerssen; H Lubatschowski; K Ursinus; H Gasse; R Koch; M Ptok
Journal:  HNO       Date:  2006-08       Impact factor: 1.284

6.  Current role of stroboscopy in laryngeal imaging.

Authors:  Daryush D Mehta; Robert E Hillman
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2012-12       Impact factor: 2.064

7.  Pre- and intraoperative assessment of mid-cord erythroleukoplakias: a prospective study on 52 patients.

Authors:  Giorgio Peretti; Cesare Piazza; Marco Berlucchi; Johnny Cappiello; Marco Giudice; Piero Nicolai
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-06-03       Impact factor: 2.503

8.  Optical coherence tomography-enhanced microlaryngoscopy: preliminary report of a noncontact optical coherence tomography system integrated with a surgical microscope.

Authors:  David E Vokes; Ryan Jackson; Shuguang Guo; Jorge A Perez; Jianping Su; James M Ridgway; William B Armstrong; Zhongping Chen; Brian J F Wong
Journal:  Ann Otol Rhinol Laryngol       Date:  2008-07       Impact factor: 1.547

9.  Cyclin D1 and cancer development in laryngeal premalignancy patients.

Authors:  Vassiliki Papadimitrakopoulou; Julie G Izzo; Diane D Liu; Jeffrey Myers; Tania L Ceron; Jan Lewin; William N William; Anthea Atwell; J Jack Lee; Ann Gillenwater; Adel El-Naggar; Xifeng Wu; Scott M Lippman; Walter N Hittelman; Waun Ki Hong
Journal:  Cancer Prev Res (Phila)       Date:  2009-01

Review 10.  Topical use of MMC in the upper aerodigestive tract: a review on the side effects.

Authors:  Egbert J D Veen; Frederik G Dikkers
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-11-17       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.